CIK 0001710072 · Large accelerated filer
Edgewise Therapeutics, Inc.
Sign in to watch- Ticker
- EWTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821725586
- Phone
- 720-262-7002
- Business address
- 1715 38TH ST, BOULDER, CO, 80301
- 4 Open-market sale Chief Financial Officer sold 4,442 shares at $45.43 ($201,787)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 8-K Event Results of operations
- 10-Q Report Quarterly Report
- 4 Grant or award Director acquired 308 shares (grant or award)
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4/A Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale CMO sold 9,441 shares at an average $43.71 ($412,703)
- 4 Open-market sale Chief Scientific Officer sold 5,901 shares at an average $43.73 ($258,042)
- 4 Open-market sale General Counsel sold 5,016 shares at an average $43.82 ($219,823)
- 4 Open-market sale Chief Business Officer sold 5,100 shares at an average $43.81 ($223,424)
- 4 Open-market sale President and CEO sold 17,971 shares at an average $43.68 ($785,042)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 144 Insider Sale of Securities
Page 1 of 22 · 423 filings